To include your compound in the COVID-19 Resource Center, submit it here.
Updated data from an open-label, dose-escalation, U.S. Phase I trial in 69 patients with advanced metastatic or
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury